Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Orsi

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Theranostics|February 28, 2019
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic AdenocarcinomaFilippo Rossignoli, Carlotta Spano, Giulia Grisendi, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genesAnna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 9, 2026
Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter studyMaria Kiriukova, Giulia Orsi, Vasile Sandru, et al.
Cancers|July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibGiorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2022
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic SamplesMiriam Redegalli, Greta Grassini, Gilda Magliacane, et al.
Scientific Reports|February 12, 2019
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic CancerCarlotta Spano, Giulia Grisendi, Giulia Golinelli, et al.
Gastrointestinal Tumors|November 27, 2019
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of ExperienceGiulia Rovesti, Giulia Orsi, Andrikou Kalliopi, et al.
Nutrients|January 11, 2025
Cell Membrane Fatty Acids and PIPs Modulate the Etiology of Pancreatic Cancer by Regulating AKTCarolina Torres, Georgina Mancinelli, Jee-Wei Emily Chen, et al.
Gastrointestinal Tumors|November 27, 2019
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation CohortAndrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, et al.
Tumori|November 27, 2020
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitusAndrea Pretta, Pina Ziranu, Marco Puzzoni, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Theranostics|February 28, 2019
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic AdenocarcinomaFilippo Rossignoli, Carlotta Spano, Giulia Grisendi, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genesAnna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 9, 2026
Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter studyMaria Kiriukova, Giulia Orsi, Vasile Sandru, et al.
Cancers|July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibGiorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2022
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic SamplesMiriam Redegalli, Greta Grassini, Gilda Magliacane, et al.
Scientific Reports|February 12, 2019
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic CancerCarlotta Spano, Giulia Grisendi, Giulia Golinelli, et al.
Gastrointestinal Tumors|November 27, 2019
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of ExperienceGiulia Rovesti, Giulia Orsi, Andrikou Kalliopi, et al.
Nutrients|January 11, 2025
Cell Membrane Fatty Acids and PIPs Modulate the Etiology of Pancreatic Cancer by Regulating AKTCarolina Torres, Georgina Mancinelli, Jee-Wei Emily Chen, et al.
Gastrointestinal Tumors|November 27, 2019
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation CohortAndrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, et al.
Tumori|November 27, 2020
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitusAndrea Pretta, Pina Ziranu, Marco Puzzoni, et al.
Pageof 6